Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
September 25, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
August 07, 2023 07:15 ET
|
Passage Bio
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
August 07, 2023 07:00 ET
|
Passage Bio
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
Passage Bio to Participate in Upcoming Investor Conferences
August 01, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 31, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
May 11, 2023 07:00 ET
|
Passage Bio
On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory...
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
May 04, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 21, 2023 16:01 ET
|
Passage Bio
PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...